Regulatory
positioning and
compounding
boundaries.
AXIONOVA™ operates under a dual-jurisdiction strategy: United States FDA primary commercial pathway and Mexico COFEPRIS home base. This statement describes jurisdictional planning and operational governance. It does not state or imply that any AXIONOVA™ compound, device, software module, AXIONOVA™ AGIS workflow, protocol structure, or AI output has received FDA approval, FDA clearance, COFEPRIS authorization, or therapeutic-use authorization unless AXIONOVA™ publishes a specific written regulatory status statement for that item.
Hi, I am ALETHA. I help you understand your data and prepare it for your practitioner. I do not make clinical decisions; your practitioner does.
ALETHRA™ governs; ALETHA™ guides. Governance framework
Compounded medications require a valid prescription.
All compounds referenced on this platform are dispensed exclusively through licensed compounding pharmacies pursuant to valid prescriptions. Compounded medications are not FDA-approved and have not undergone premarket review for safety or efficacy. Compounds, protocol structures, stack logic, device workflows, biometric intelligence outputs, and public education materials are not represented as FDA-approved treatments, cures, diagnostic tools, disease-prevention products, emergency services, or substitutes for licensed clinical judgment. Professional use, telehealth oversight, imports, exports, distribution, advertising, privacy, data protection, and emergency-response workflows must be reviewed under the applicable legal and regulatory framework before implementation.
U.S. FDA primary commercial pathway · Mexico COFEPRIS home base. This jurisdiction statement does not imply FDA approval, COFEPRIS authorization, product clearance, device clearance, or therapeutic authorization.
Review the boundaries that govern access.
Access to AXIONOVA™ materials and workflows is governed through documented oversight and prescription-based access boundaries. Review the Compounding & Platform Disclaimer and Terms of Use, or request review through Clinical Access.